Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting β 2-agonist, in different ethnic populations

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 8, 2012, Pages 545-556

  Matsushima, Soichiro ^a   Matthews, Ivan ^b   Woessner, Ralph ^b   Pinault, Gregory ^b   Hara, Hisanori ^b   Wilkins, Justin ^b   Sekiguchi, Kaneo ^a  

^a NOVARTIS PHARMA K K   (Japan)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Ethnic insensitivity; Indacaterol; Systemic pharmacokinetics

Indexed keywords

INDACATEROL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SENSITIVITY; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; SINGLE DRUG DOSE; STEADY STATE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASIAN CONTINENTAL ANCESTRY GROUP; DELAYED-ACTION PREPARATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INDANS; MALE; MODELS, STATISTICAL; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864597345     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201719     Document Type: Article

References (19)

1. Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005; 14: 775-783. doi:10.1517/13543784.14.7.775 PubMed (Pubitemid 41030946)
2. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B. INLIGHT 1 study group. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010; 10: 11. doi:10.1186/1471-2466-10-11 PubMed
3. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182: 155-162. doi:10.1164/rccm.200910-1500OC PubMed
4. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo controlled comparison. Eur Respir J. 2011; 37: 273-279. doi:10.1183/09031936.00045810 PubMed
5. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B. INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax. 2010; 65: 473-479. doi:10.1136/thx.2009.125435 PubMed
6. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B; INDORSE Study Investigators. Long-term safety and efficacy of indacaterol, a long-acting beta-2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011; 140: 68-75. doi:10.1378/chest.10-1830 PubMed
7. Kato M, Makita H, Uemura K, Fukuchi Y, Hosoe M, Emery C, Higgins M, Kramer B. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial. Allergol Int. 2010; 59: 285-293. doi:10.2332/allergolint.10-OA-0173 PubMed
8. Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y; Indacaterol Asian COPD study investigators. Efficacy and safety of indacaterol 150 and 300g in Asian COPD Patients: A 12-week, placebo controlled study. Am J Respir Crit Care Med. 2011; 183: A1593.
9. Hosoe M, Woessner R, Matsushima S, Lawrence D, Kramer B. Efficacy and pharmacokinetics of indacaterol in Caucasian and Japanese COPD patients: a comparison of two placebo-controlled studies. Clin Drug Investig. 2011; 31: 247-255. doi:10.2165/11586520-000000000-00000 PubMed
10. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008; 84: 417-423. doi:10.1038/clpt.2008.141 PubMed
11. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004; 44: 1083-1105. doi:10.1177/0091270004268128 PubMed (Pubitemid 39202454)
12. Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS, Murphy WR, Roman K, Schneck D, Sonnichsen DS, Stalker DJ, Wise SD, Dombey S, Loew C. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003; 43: 943-967. doi:10.1177/ 0091270003256065 PubMed (Pubitemid 37022739)
13. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009. At: www.goldcopd.com (accessed 17 February 2010).
14. Khindri S, Sabo R, Harris S, Woessner R, Jennings S, Drollmann AF. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med. 2011; 11: 31-38. doi:10.1186/1471-2466-11-31 PubMed
15. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004; 75: 85-94. doi:10.1016/j.cmpb.2003.11.003 PubMed (Pubitemid 38798039)
16. Food and Drug Administration. Guidance for industry. Population pharmacokinetics. 1999. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf (accessed on 18th July 2011).
17. Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother. 2004; 38: 1907-1915. doi:10.1345/aph.1E259 PubMed (Pubitemid 39425727)
18. Heeremans EH, Proost JH, Eleveld DJ, Absalom AR, Struys MMRF. Population pharmacokinetics and pharmacodynamics in anesthesia, intensive care and pain medicine. Curr Opin Anaesthesiol. 2010; 23: 479-484. doi:10.1097/ACO. 0b013e32833a1d2f PubMed
19. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 2000; 55: 650-656. doi:10.1136/thorax.55.8.650 PubMed (Pubitemid 30468219)